Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed
Data up to Jan 2025
Total Citations Per Year
Abstract
References (13)
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 • 10,779 citations
The biology of VEGF and its receptors
2003 • 9,272 citations
Exploiting tumour hypoxia in cancer treatment
2004 • 2,606 citations
Clinical translation of angiogenesis inhibitors
2002 • 1,518 citations
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
2000 • 1,159 citations
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
1997 • 832 citations
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents
1991 • 441 citations
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
2002 • 427 citations
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
2005 • 400 citations
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis
2002 • 372 citations
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004 • 86 citations
Encouraging Results for Second-Generation Antiangiogenesis Drugs
2005 • 51 citations
Calculated resistance in cancer
2005 • 26 citations